Table 3 Management of 26 patients with Multisystem Inflammatory Syndrome in Children in Michigan, April 2020 – February 2021
Treatment | ||||
|---|---|---|---|---|
| Â | Total (%) | Group 1 (PICU) (%) | Group 2 (non-PICU) (%) | p values |
Total | 26 | 15 | 11 | |
Inotropesa | 12 (46.2) | 12 (80) | 0 (0) | 0.0001* |
Aspirin | 25 (96.2) | 15 (100) | 10 (90.9) | 0.4231 |
Low-molecular weight heparin | 12 (46.2) | 9 (60) | 3 (27.3) | 0.0982 |
Heparin | 5 (19.2) | 5 (33.3) | 0 (0) | 0.0527 |
IVIG | 25 (96.2) | 15 (100) | 10 (90.9) | 0.4231 |
Steroids | 22 (84.6) | 13 (86.7) | 9 (81.8) | 1.0 |
Steroid pulse | 7 (26.9) | 6 (40) | 1 (9.1) | 0.1783 |
Anakinra | 13 (50) | 10 (66.7) | 3 (27.3) | 0.0472* |
Infliximab | 1 (3.9) | 1 (6.7) | 0 (0) | 1.0 |